Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis

被引：2

作者：

van der Weele, Linda ^{[1
,2
]}

Pollastro, Sabrina ^{[1
,2
]}

van Schaik, Barbera D. C. ^{[3
]}

van Kampen, Antoine H. C. ^{[3
]}

Niewold, Ilse T. G. ^{[1
]}

Kuijpers, Taco W. ^{[4
]}

Warnke, Clemens ^{[5
]}

Jensen, Poul Erik H. ^{[6
]}

Kramer, Daniel ^{[7
]}

Ryner, Malin ^{[8
]}

Hermanrud, Christina ^{[8
]}

Donnes, Pierre ^{[9
]}

Pallardy, Marc ^{[10
]}

Spindeldreher, Sebastian ^{[11
]}

Deisenhammer, Florian ^{[12
]}

Fogdell-Hahn, Anna ^{[8
]}

de Vries, Niek ^{[1
,2
,13
]}

机构：

[1] Univ Amsterdam, Dept Clin Immunol & Rheumatol, Locat AMC, Amsterdam Rheumatol & Immunol Ctr ARC,Amsterdam UM, Amsterdam, Netherlands

[2] Univ Amsterdam, Amsterdam Infect & Immun Inst AIII, Dept Expt Immunol, Amsterdam UMC,Locat AMC, Amsterdam, Netherlands

[3] Univ Amsterdam, Amsterdam Infect & Immun Inst AIII, Amsterdam Publ Hlth Res Inst, Dept Clin Epidemiol Biostat & Bioinformat,Amsterda, Amsterdam, Netherlands

[4] Univ Amsterdam, Emma Childrens Hosp, Dept Pediat Immunol Rheumatol & Infect Dis, Amsterdam UMC,Locat AMC, Amsterdam, Netherlands

[5] Univ Hosp Cologne, Med Fac, Dept Neurol, Cologne, Germany

[6] Univ Copenhagen, Danish Multiple Sclerosis Ctr, Dept Neurol, Rigshospitalet, Copenhagen, Denmark

[7] Sanofi Aventis Germany, Frankfurt, Germany

[8] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden

[9] SciCross AB, Skovde, Sweden

[10] Univ Paris Saclay, Fac Pharm, INSERM, Inflammat Microbiome Immunopathol, Chatenay Malabry, France

[11] Integrated Biologix GmbH, Basel, Switzerland

[12] Innsbruck Med Univ, Innsbruck, Austria

[13] Univ Amsterdam, Dept Clin Immunol & Rheumatol, Amsterdam UMC, Locat AMC,Amsterdam Rheumatol & Immunol Ctr ARC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2022年 / 370卷

关键词：

Multiple sclerosis; Interferon beta; B-cell receptor; Adaptive immune receptor repertoire; Next generation sequencing; Anti-drug antibody; NEUTRALIZING ANTIBODIES; IFN-BETA; RELEVANCE;

D O I：

10.1016/j.jneuroim.2022.577932

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif (TM)) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized that high-throughput B-cell receptor (BCR) repertoire analysis could be used to predict and monitor ADA development. To study this we analyzed 228 peripheral blood samples from 68 longitudinally followed patients starting on interferon beta-1a. Our results show that whole blood BCR analysis does not reflect, and does not predict ADA development in MS patients treated with interferon beta-1a. We propose that BCR analysis of phenotypically selected cell subsets or tissues might be more informative.

引用

页数：7

共 32 条

[11] Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients [J].